Viatris Inc. (NasdaqGS: VTRS)
Health Care · Pharmaceuticals · US
$17.54
-0.57% today · +76.6% 1Y
Viatris Inc. (NasdaqGS: VTRS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $20.26B and employs 30,000 people.
Over the last twelve months the share price has gained 76.6%, trading between 9.69 and 18.43.
Tweenvest scores Viatris Inc. across four factors: quality 67/100, value 33/100, growth 0/100, dividend 92/100. Its strongest factor is dividend.
VTRS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.26B
- Revenue (TTM)
- $14.74B
- P/E
- —
- EPS
- -0.35
- Dividend yield
- 2.75%
- Beta (5Y)
- 0.86
- 52-week high
- $18.43
- 52-week low
- $9.69
- Avg volume (3M)
- —
- Shares outstanding
- 1.15B
- Employees
- 30,000
- Next earnings
- —
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- ISIN
- US92556V1061
- Founded
- 1961
- Listed since
- Mar 17, 1980
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Daiichi Sankyo Company, LimitedTSE: 4568 | $30.16B | ¥2,623.00 | -3.17% |
| Astellas Pharma Inc.TSE: 4503 | $25.45B | ¥2,247.50 | -0.02% |
| Royalty Pharma plcNasdaqGS: RPRX | $25.35B | $57.23 | +0.53% |
| Hansoh Pharmaceutical Group Company LimitedSEHK: 3692 | $24.37B | HK$31.54 | -1.99% |
| Torrent Pharmaceuticals LimitedBSE: 500420 | $18.31B | Rs4,660.00 | -2.14% |
| Shionogi & Co., Ltd.TSE: 4507 | $14.75B | ¥2,744.50 | -0.88% |
| Jazz Pharmaceuticals plcNasdaqGS: JAZZ | $14.18B | $218.81 | +0.18% |
| Sichuan Biokin Pharmaceutical Co.,Ltd.SHSE: 688506 | $14.14B | CN¥229.33 | -5.24% |
Figures last refreshed Oct 11, 2026.